Third, the pleiotropic cardioprotective effects of SGLT2 inhibitors (natriuresis, blood pressure reduction, and improved endothelial function) might require longer follow-ups durations or occur predominantly in patients with metabolic disturbances such as insulin resistance or hyperglycemia. The gene discussed is SLC5A2; the disease is Insulin resistance.